The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
41
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Week 53
Pharmacokinetics (PK):Area Under the Concentration Versus Time Curve (AUC) of LY3875383
PK: AUC of LY3875383
Time frame: Predose up to Day 8 post dose
PK: Maximum Observed Concentration (Cmax) of LY3875383
PK: Cmax of LY3875383
Time frame: Predose up to Day 8 post dose
Part C and D only: Pharmacodynamics (PD): Percentage Change from Baseline in Fasting Triglyceride (TG)
Part C and D only: PD: Percentage Change from Baseline in Fasting TG
Time frame: Baseline through up to Week 53
Part D only: PD: Percentage Change from Baseline in Fasting Non-High-Density Lipoprotein Cholesterol (HDL-C)
Part D only: PD: Percentage Change from Baseline in Fasting non-HDL-C
Time frame: Baseline through Week 53
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.